Eli Lilly aims to introduce orforglipron, its once-daily oral GLP-1 drug for obesity, in India by H2 2026, targeting patients with BMI 27-34 seeking 12-16% weight loss without injections.
Following Mounjaro’s blockbuster sales doubling post-March 2025 launch to ₹114 crore in March 2026, Lilly eyes regulatory submission by year-end, prioritizing India in global filings due to oral preference (75% patient uptake). The small-molecule pill avoids cold chains, aiding rural reach versus injectables.
Market Opportunity
India’s ₹752 crore anti-obesity sector could hit ₹800 crore by 2030; orforglipron competes with cheaper semaglutide generics eroding Mounjaro’s lead. Lilly leverages Cipla/1MG partnerships for expansion, pricing competitively post-approval.
